Orthopediatrics Corp (KIDS) Peer Comparison

$22.22

$-0.19 (-0.85%)

As on 08-Sep-2026 16:00EDT

Market cap

$585 Mln

Revenue (TTM)

$253 Mln

P/E Ratio

--

P/B Ratio

1.7

Div. Yield

0 %

Edit

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	585	12,650	10,638	9,762	9,459
Revenue ($ Mln)	253	1,505	613	2,589	785
Net Profit ($ Mln)	-39.73	160.59	-188.05	222.40	41.54
Net Margin (%)	-15.72	10.67	-30.68	8.59	5.29
RoE (%)	-11.51	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.29	--	44.47	232.78
Price-To-Book	1.72	8.31	15.27	1.36	4.62

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	252.73	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	66.59	483.98	127.96	1,245.50	384.30
Gross Profit	172.66	942.44	393.22	1,343.60	347.62
Operating Expenses	208.91	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-22.78	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-39.45	203.83	-192.83	350.40	52.15
Provision for Tax	0.28	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-39.73	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	343.61	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	106.88	210.18	135.71	2,116.80	705.49
Current Liabilities	52.85	233.78	102.33	961.30	132.66
Total Liabilities	508.63	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	258.88	630.60	404.74	7,231.50	1,749.63
Current Assets	252.51	1,344.12	515.78	3,020.50	1,200.55
Total Assets	508.63	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	91.59	212.71	102.84	1,203.70	690.94
Net Current Assets	199.66	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-4.85	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-43.63	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	23.98	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-8.99	11.76	-22.53	8.98	1.79
ROE (%)	-11.51	10.86	-28.10	3.04	1.97
ROA (%)	-7.18	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-8.89	13.63	-30.58	-5.99	9.87
Net Margin (%)	-15.72	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	14.49	17.55	41.55	1.37	16.49
EBIT Growth (%)	31.04	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	4.87	8.72	-102.66	-30.32	400.42
EPS Growth (%)	6.46	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-5.46	17.33	-12.65	2.19	2.16

Valuation Ratios

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-10.56	68.93	-34.59	--	189.42
Price / Book Value	1.21	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-38.33	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.29	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.00	0.01	0.00	0.06	0.01
Current Ratio	4.78	5.75	5.04	3.14	9.05
Quick Ratio	2.17	3.86	4.46	2.33	7.64
Interest Coverage	-3.71	157.91	-38.31	8.18	1.92

Operating Efficiency Ratios

	Orthopediatrics Corp (KIDS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	24.12	12.65	22.67	17.06	20.09
Asset Turnover	0.46	0.74	0.59	0.24	0.26
Receivable days	74.33	46.54	60.95	65.39	72.41
Inventory Days	719.16	331.92	193.84	221.09	146.53
Payable days	79.41	26.16	60.19	37.02	29.05
Cash Conversion Cycle	714.08	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly